Balance Sheet Breakdown: Kymera Therapeutics Inc (KYMR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.

After finishing at $44.2 in the prior trading day, Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $43.7, down -1.13%. In other words, the price has decreased by -$1.13 from its previous closing price. On the day, 0.6 million shares were traded. KYMR stock price reached its highest trading level at $44.57 during the session, while it also had its lowest trading level at $43.21.

Ratios:

Our goal is to gain a better understanding of KYMR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.49 and its Current Ratio is at 8.49. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.

On June 03, 2025, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $79.

B. Riley Securities Upgraded its Neutral to Buy on June 03, 2025, while the target price for the stock was maintained at $60.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 30 ’25 when BVF PARTNERS L P/IL bought 317,167 shares for $44.00 per share. The transaction valued at 13,955,348 led to the insider holds 2,798,795 shares of the business.

BAKER BROS. ADVISORS LP bought 655,500 shares of KYMR for $28,842,000 on Jun 30 ’25. The Director now owns 6,117,295 shares after completing the transaction at $44.00 per share. On Jun 11 ’25, another insider, Ridloff Elena, who serves as the Director of the company, sold 4,500 shares for $50.00 each. As a result, the insider received 225,000 and left with 0 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 3065869568 and an Enterprise Value of 2468905216. For the stock, the TTM Price-to-Sale (P/S) ratio is 52.07 while its Price-to-Book (P/B) ratio in mrq is 3.62. Its current Enterprise Value per Revenue stands at 41.928 whereas that against EBITDA is -9.088.

Stock Price History:

The Beta on a monthly basis for KYMR is 2.18, which has changed by -0.054112554 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $53.27, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is 2.94%, while the 200-Day Moving Average is calculated to be 11.34%.

Shares Statistics:

The stock has traded on average 863.78K shares per day over the past 3-months and 502650 shares per day over the last 10 days, according to various share statistics. A total of 65.11M shares are outstanding, with a floating share count of 58.31M. Insiders hold about 16.89% of the company’s shares, while institutions hold 90.45% stake in the company. Shares short for KYMR as of 1752537600 were 7572642 with a Short Ratio of 8.77, compared to 1749772800 on 7582895. Therefore, it implies a Short% of Shares Outstanding of 7572642 and a Short% of Float of 13.38.

Dividends & Splits

Against a Trailing Annual Dividend Yield of 0.0

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.